ASP0598 / Auration Biotech, Astellas - LARVOL DELTA

A Study to Assess ASP0598 Otic Solution Following Topical Application in the Ear in Subjects With Chronic Tympanic Membrane Perforation (CTMP) (clinicaltrials.gov) - P1/2 | N=36 | Terminated | Sponsor: Astellas Pharma Global Development, Inc. | N=114 ➔ 36 | Trial completion date: Jun 2024 ➔ Jan 2023 | Recruiting ➔ Terminated | Trial primary completion date: Jun 2024 ➔ Jan 2023; Lack of Efficacy

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Otorhinolaryngology